4 results
DEF 14A
Core Laboratories Inc.
18 Mar 24
Definitive proxy
6:07pm
The tables below reflect the amount of compensation that would be payable to each of Messrs. Bruno, Hill, Ms. Gresham and Mr. Tattoli in various scenarios involving termination of the NEO’s employment, including following a change in control. The amount of compensation payable to each applicable NEO upon voluntary termination, involuntary not-for-cause termination (non-change in control), voluntary termination for good cause or involuntary termination following a change in control, involuntary for cause termination, and termination in the event of death or disability of each applicable NEO is shown below. The amounts shown assume that the termination was effective on December 31, 2023, and thus includes amounts earned through that time and are estimates of the amounts which would be paid out to the applicable NEOs upon their termination. The amounts payable upon termination following a change in control assume that the change in control occurred on December 31, 2023, and the termination was effective the same day. The actual amounts to be paid out can only be determined at the time of the applicable NEO’s separation from us. Each NEO would also have available the value of unvested shares reflected in the Outstanding Equity Awards at Fiscal Year End table, if any. The value of accelerated equity award amounts reflected below have been calculated using the closing price of our common stock on December 29, 2023 (the last trading day of 2023) of $17.66.
Lawrence Bruno | Voluntary Termination on 12/31/2023 (1) ($) | Involuntary Not For Cause Termination on 12/31/2023 (1) ($) | For Cause Termination on 12/31/2023 ($) | Termination related to Change-in- Control on 12/31/2023 ($) | Disability on 12/31/2023 (1) ($) | Death on 12/31/2023 (1) ($) | ||||||||||||||||||
Compensation: | ||||||||||||||||||||||||
Severance | — | 1,773,824 | — | 5,321,472 | — | — | ||||||||||||||||||
Short-term Incentive | — | 886,912 | — | 886,912 | — | — | ||||||||||||||||||
Long-term Incentives: | ||||||||||||||||||||||||
Accelerated Equity Award Programs | — | 8,169,640 | — | 8,169,640 | 8,169,640 | 8,169,640 | ||||||||||||||||||
Benefits & Perquisites: | ||||||||||||||||||||||||
Health and Welfare Benefits | 382,700 | 382,700 | — | 382,700 | — | — | ||||||||||||||||||
Outplacement Services | — | 25,000 | — | 25,000 | — | — | ||||||||||||||||||
Accelerated Deferred Comp | — | — | — | — | — | — | ||||||||||||||||||
Total | 382,700 | 11,238,076 | — | 14,785,724 | 8,169,640 | 8,169,640 |
DEF 14A
Core Laboratories Inc.
18 Mar 24
Definitive proxy
6:07pm
Mark D. Tattoli | Voluntary Termination on 12/31/2023 (1) ($) | Involuntary Not For Cause Termination on 12/31/2023 (1) ($) | For Cause Termination on 12/31/2023 ($) | Termination related to Change-in- Control on 12/31/2023 ($) | Disability on 12/31/2023 (1) ($) | Death on 12/31/2023 (1) ($) | ||||||||||||||||||
Compensation: | ||||||||||||||||||||||||
Severance | — | 611,832 | — | 1,784,510 | — | — | ||||||||||||||||||
Short-term Incentive | — | 305,916 | — | 305,916 | — | — | ||||||||||||||||||
Long-term Incentives: | ||||||||||||||||||||||||
Accelerated Equity Award Programs | — | 1,205,012 | — | 1,205,012 | 1,205,012 | 1,205,012 | ||||||||||||||||||
Benefits & Perquisites: | ||||||||||||||||||||||||
Health and Welfare Benefits | 551,600 | 551,600 | — | 551,600 | — | — | ||||||||||||||||||
Outplacement Services | — | 25,000 | — | 25,000 | — | — | ||||||||||||||||||
Accelerated Deferred Comp | — | 73,500 | — | 73,500 | 73,500 | 73,500 | ||||||||||||||||||
Total | 551,600 | 2,772,860 | — | 3,945,538 | 1,278,512 | 1,278,512 |
DEF 14A
Core Laboratories Inc.
18 Mar 24
Definitive proxy
6:07pm
Christopher S. Hill | Voluntary Termination on 12/31/2023 (1) ($) | Involuntary Not For Cause Termination on 12/31/2023 (1) ($) | For Cause Termination on 12/31/2023 ($) | Termination related to Change-in- Control on 12/31/2023 ($) | Disability on 12/31/2023 (1) ($) | Death on 12/31/2023 (1) ($) | ||||||||||||||||||
Compensation: | ||||||||||||||||||||||||
Severance | — | 697,632 | — | 2,034,760 | — | — | ||||||||||||||||||
Short-term Incentive | — | 348,816 | — | 348,816 | — | — | ||||||||||||||||||
Long-term Incentives: | ||||||||||||||||||||||||
Accelerated Equity Award Programs | — | 2,774,580 | — | 2,774,580 | 2,774,580 | 2,774,580 | ||||||||||||||||||
Benefits & Perquisites: | ||||||||||||||||||||||||
Health and Welfare Benefits | 475,000 | 475,000 | — | 475,000 | — | — | ||||||||||||||||||
Outplacement Services | — | 25,000 | — | 25,000 | — | — | ||||||||||||||||||
Accelerated Deferred Comp | — | 130,800 | — | 130,800 | 130,800 | 130,800 | ||||||||||||||||||
Total | 475,000 | 4,451,828 | — | 5,788,956 | 2,905,380 | 2,905,380 |
DEF 14A
Core Laboratories Inc.
18 Mar 24
Definitive proxy
6:07pm
Gwendolyn Y. Gresham | Voluntary Termination on 12/31/2023 (1) ($) | Involuntary Not For Cause Termination on 12/31/2023 (1) ($) | For Cause Termination on 12/31/2023 ($) | Termination related to Change-in- Control on 12/31/2023 ($) | Disability on 12/31/2023 (1) ($) | Death on 12/31/2023 (1) ($) | ||||||||||||||||||
Compensation: | ||||||||||||||||||||||||
Severance | — | 611,832 | — | 1,784,510 | — | — | ||||||||||||||||||
Short-term Incentive | — | 305,916 | — | 305,916 | — | — | ||||||||||||||||||
Long-term Incentives: | ||||||||||||||||||||||||
Accelerated Equity Award Programs | — | 1,127,838 | — | 1,127,838 | 1,127,838 | 1,127,838 | ||||||||||||||||||
Benefits & Perquisites: | ||||||||||||||||||||||||
Health and Welfare Benefits | 363,300 | 363,300 | — | 363,300 | — | — | ||||||||||||||||||
Outplacement Services | — | 25,000 | — | 25,000 | — | — | ||||||||||||||||||
Accelerated Deferred Comp | — | 112,500 | — | 112,500 | 112,500 | 112,500 | ||||||||||||||||||
Total | 363,300 | 2,546,386 | — | 3,719,064 | 1,240,338 | 1,240,338 |
- Prev
- 1
- Next